Por: The Boston Globe Business January 30, 2023
Given everything he’s been through, Bobby Wiseman says he should have been dead instead of celebrating the birth of his first grandchild several days ago.Wiseman, 51, who lives near Sacramento, was diagnosed as an infant with hemophilia, the rare genetic disease that prevents blood from clotting. He tested positive for HIV and hepatitis C when he was 11 after catching the viruses from contaminated blood-clotting products. As a teenager, he... + full article
Ars Technica USA Science January 05, 2023
Navigate Filter by topic Settings Front page layout Site theme - Jan 5, 2023 12:45 pm UTC MARK GARLICK/SCIENCE PHOTO LIBRARY Share this story Gene therapy has had a long and bumpy history. Although researchers have made some notable and Despite these issues, experts say there... + más
Opinion | The New York Times
First participant in test of custom gene editing therapy dies | The Boston Globe
The New York Times USA Opinion December 09, 2022
The parents of a 2-year-old girl write that their daughter “could die within the next year” because a genetic mutation is causing her heart to fail.“Time is quickly running out for me,” writes a man in his mid-30s whose DNA harbors a genetic mistake certain to destroy... + más
Justice Alito accused of being SCOTUS leaker after new report: Disgrace | Newsweek
Why would Mac Jones get a second opinion on his injury, and how common is that? | The Boston Globe
ABC News USA Health November 23, 2022
WASHINGTON -- U.S. regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common form of the... + más
FDA approves most expensive drug ever, $3.5 million-per-dose gene therapy for hemophilia B | CBS News
$3.5M gene therapy for hemophilia gets FDA approval | WPLG Local 10
WPLG Local 10 USA Health November 23, 2022
WASHINGTON – U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
$3.5M gene therapy for hemophilia gets FDA approval | ABC News
CBS News USA Health November 23, 2022
Washington — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder. The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less common... + más
Associated Press USA Science November 23, 2022
WASHINGTON (AP) — U.S. health regulators on Tuesday approved the first gene therapy for hemophilia, a $3.5 million one-time treatment for the blood-clotting disorder.The Food and Drug Administration cleared Hemgenix, an IV treatment for adults with hemophilia B, the less... + más
The Advocate USA Entertainment November 11, 2022
The Inter-Civic Council of Greater Baton Rouge gathered at Hunan’s Chinese Restaurant on Oct. 11 and welcomed guest speaker Ashley Castello, executive director of the Louisiana Hemophilia Foundation, who gave an encouraging report on the medical and social aspects of... + más
About iurex | Privacy Policy | Disclaimer |